S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
Freshworks gets juiced on its AI customer engagement platform
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
Much of Kenya falls into darkness in the third nationwide power blackout in 3 months
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
Freshworks gets juiced on its AI customer engagement platform
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
Much of Kenya falls into darkness in the third nationwide power blackout in 3 months
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
Freshworks gets juiced on its AI customer engagement platform
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
Much of Kenya falls into darkness in the third nationwide power blackout in 3 months
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
Freshworks gets juiced on its AI customer engagement platform
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
Much of Kenya falls into darkness in the third nationwide power blackout in 3 months

Bionano Genomics (BNGO) Stock Forecast & Price Target

$1.47
-0.05 (-3.29%)
(As of 12/8/2023 08:56 PM ET)
Compare
Today's Range
$1.45
$1.57
50-Day Range
$1.26
$2.95
52-Week Range
$1.19
$22.40
Volume
1.05 million shs
Average Volume
912,711 shs
Market Capitalization
$57.09 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$47.00

Bionano Genomics Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Moderate Buy
Based on 4 Analyst Ratings

Analysts' Consensus Price Target

$47.00
3,097.28% Upside
High Forecast$90.00
Average Forecast$47.00
Low Forecast$10.00
TypeCurrent Forecast
12/11/22 to 12/11/23
1 Month Ago
11/11/22 to 11/11/23
3 Months Ago
9/12/22 to 9/12/23
1 Year Ago
12/11/21 to 12/11/22
Consensus Rating
Moderate Buy
Buy
Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
3 Buy rating(s)
3 Buy rating(s)
3 Buy rating(s)
2 Buy rating(s)
Hold
1 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$47.00$47.00$47.00$95.00
Predicted Upside3,097.28% Upside299.47% Upside299.47% Upside375.59% Upside
Get Bionano Genomics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for BNGO and its competitors with MarketBeat's FREE daily newsletter.


BNGO Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

BNGO Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Bionano Genomics Stock vs. The Competition

TypeBionano GenomicsMedical CompaniesS&P 500
Consensus Rating Score
2.75
2.67
2.49
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside3,097.28% Upside737.73% Upside3,819.11% Upside
News Sentiment RatingNegative News
Positive News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/13/2023Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Hold
8/10/2023BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$10.00+157.73%
5/10/2023LADENBURG THALM/SH SH
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$60.00 ➝ $48.00+548.65%
2/6/2023Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform$120.00 ➝ $90.00+381.28%
1/4/2023Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageSector Outperform$40.00+168.46%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 03:21 AM ET.












BNGO Price Target - Frequently Asked Questions

What is Bionano Genomics's consensus rating and price target?

According to the issued ratings of 4 analysts in the last year, the consensus rating for Bionano Genomics stock is Moderate Buy based on the current 1 hold rating and 3 buy ratings for BNGO. The average twelve-month price prediction for Bionano Genomics is $47.00 with a high price target of $90.00 and a low price target of $10.00. Learn more on BNGO's analyst rating history.

Do Wall Street analysts like Bionano Genomics more than its competitors?

Analysts like Bionano Genomics more than other Medical companies. The consensus rating score for Bionano Genomics is 2.75 while the average consensus rating score for medical companies is 2.67. Learn more on how BNGO compares to other companies.

Does Bionano Genomics's stock price have much upside?

According to analysts, Bionano Genomics's stock has a predicted upside of 299.47% based on their 12-month stock forecasts.

What analysts cover Bionano Genomics?

Bionano Genomics has been rated by Maxim Group in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:BNGO) was last updated on 12/11/2023 by MarketBeat.com Staff

My Account -